HCR 040
Alternative Names: HCR-040Latest Information Update: 04 Mar 2024
At a glance
- Originator Histocell
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Adult respiratory distress syndrome
Most Recent Events
- 27 Feb 2022 Histocell completes a Phase-I/II clinical trials in Adult espiratory distress syndrome in Spain (IV) (EudraCT2019-002688-89) (NCT04289194)
- 30 Jan 2020 The Spanish Agency of Medicines and Medical Devices approves phase I/II trial for Respiratory distress syndrome in Spain before January 2020 (Histocell website, January 2020)
- 10 Dec 2019 Phase-I/II clinical trials in Adult espiratory distress syndrome in Spain (IV) (EudraCT2019-002688-89) (NCT04289194)